Zacks Investment Research Upgrades Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) to “Hold”

Share on StockTwits

Zacks Investment Research upgraded shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) from a sell rating to a hold rating in a research report released on Tuesday, Zacks.com reports.

According to Zacks, “Swedish Orphan Biovitrum is a biotechnology company. It develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio consists of Core Products segment which offers pharmaceuticals within Inflammation area and Genetics and metabolic therapeutic area; Partner Products segment which offers pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The company operates primarily in Sweden, Denmark, Finland, Norway, United Kingdom and France. Swedish Orphan Biovitrum is based in Solna, Sweden. “

Separately, Deutsche Bank downgraded Swedish Orphan Biovitrum AB (publ) from a buy rating to a hold rating in a research note on Thursday, July 18th.

Shares of OTCMKTS:BIOVF opened at $17.00 on Tuesday. The company’s 50 day moving average is $18.65. The company has a quick ratio of 0.55, a current ratio of 0.75 and a debt-to-equity ratio of 0.39. Swedish Orphan Biovitrum AB has a 12-month low of $16.35 and a 12-month high of $21.20.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.

See Also: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Swedish Orphan Biovitrum AB (publ) (BIOVF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.